Tel Aviv, Israel

Grégory Ramniceanu

This inventor holds 1 USPTO granted patent and 2 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Ecole Nationale Superieure De Chimie De Paris, Institut National De La Santé Et De La Recherche Médicale (Inserm). Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Grégory Ramniceanu. Retrieved from https://idiyas.com/inventor/grégory-ramniceanu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Grégory Ramniceanu: Innovator in Drug Delivery Systems

Introduction

Grégory Ramniceanu is an inventive mind based in Tel Aviv, Israel. He has made significant contributions to the field of drug delivery systems through his research and development efforts. Although he currently holds no granted patents, his work in the area of amphiphilic copolymers has the potential to impact medical applications significantly.

Latest Patent Applications

One of his notable patent applications is titled "STIMULI - OR BIO- RESPONSIVE COPOLYMERS, THE POLYMERSOMES COMPRISING THE SAME AND THEIR USE IN DRUG DELIVERY." This invention focuses on amphiphilic copolymers that can be photo- or redox-cleavable, allowing them to assemble into polymersomes. The application also details the process of preparation and their use as drug carriers.

Conclusion

Grégory Ramniceanu's innovative approach to drug delivery systems showcases his dedication to advancing medical technology. His research in amphiphilic copolymers may pave the way for future breakthroughs in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…